• Magneto-Piezoelectric Scaffolds Activate JAK2-STAT3 for Bone

  2026-06-22

  Wu et al. engineered multifunctional scaffolds embedding magneto-piezoelectric nanoparticles to target Icam1+ macrophages in infectious bone defects. By activating oxidative phosphorylation through JAK2-STAT3 signaling and disrupting bacterial biofilms, this approach offers a dual mechanism for infection control and enhanced bone regeneration.

• Brain-to-Spinal Circuits Regulate Mechanical Allodynia Later

  2026-06-22

  This study systematically maps a brain-to-spinal circuit that controls both the laterality and duration of mechanical allodynia in mice. By delineating the roles of specific neuronal populations and their interactions, the work advances mechanistic understanding of bilateral pain hypersensitivity and offers a foundation for targeted preclinical research.

• Refining In Vitro Drug Response Metrics in Cancer Research

  2026-06-21

  Schwartz's dissertation introduces critical distinctions between relative and fractional viability in evaluating anticancer drug responses in vitro. By dissecting how proliferation arrest and cell death contribute separately to overall drug efficacy, this work guides more precise experimental interpretation and supports improved translational relevance for preclinical cancer drug assessment.

• Super-Enhancer RNA Drives NPC Metastasis via NPM1/c-Myc/NDRG

  2026-06-20

  This study identifies a carcinogen-induced super-enhancer RNA (seRNA-NPCm) as a driver of nasopharyngeal carcinoma (NPC) metastasis by modulating the NPM1/c-Myc/NDRG1 axis. The findings clarify the molecular mechanisms linking chemical carcinogen exposure to metastatic progression in NPC and highlight new avenues for functional genomics and biomarker research.

• Fasudil (HA-1077) HCl: Precision ROCK Inhibition for Cell As

  2026-06-19

  Fasudil (HA-1077) HCl empowers researchers with highly selective, reproducible ROCK pathway inhibition, enabling fine control of cell proliferation, migration, and apoptosis in cancer and disease models. This article details best-practice workflows, troubleshooting strategies, and new insights from Hippo pathway research to accelerate discovery.

• Novobiocin: Applied Workflows in Antiparasitic & Antiviral R

  2026-06-19

  Novobiocin, a dual-action aminocoumarin antibiotic, enables advanced research into bacterial resistance, antiparasitic, and antiviral mechanisms. This guide translates mechanistic insights and new synergy findings into optimized experimental workflows and troubleshooting strategies for use in modern drug discovery and infection biology.

• Antiplasmodial Activity of Bestatin-Related Inhibitor Phebes

  2026-06-18

  This study identifies and characterizes phebestin, a bestatin-related aminopeptidase inhibitor, as a potent antiplasmodial compound effective against both chloroquine-sensitive and -resistant Plasmodium falciparum strains. Its efficacy in vitro and in vivo, alongside a favorable cytotoxicity profile, highlights the therapeutic potential of aminopeptidase inhibition in malaria drug discovery.

• Thapsigargin: SERCA Pump Inhibitor for Advanced ER Stress As

  2026-06-18

  Thapsigargin enables precise manipulation of intracellular calcium, unlocking advanced endoplasmic reticulum stress and apoptosis assays. Its nanomolar potency and reproducibility empower researchers to dissect calcium signaling and stress responses with confidence.

• Sodium Nitroprusside: Optimizing Nitric Oxide Donor Use in V

  2026-06-17

  Sodium Nitroprusside, a potent nitric oxide donor, is central to dissecting mechanisms of vascular smooth muscle relaxation and platelet aggregation inhibition, especially in complex hypertension models. This guide delivers actionable experimental workflows and troubleshooting tactics, translating the latest sex-difference hypertension research into practical assay optimization.

• Thrombin in Advanced Fibrin Assays: Protocols & Optimization

  2026-06-17

  Unlock next-generation coagulation and angiogenesis research with high-purity thrombin B chain fragment from APExBIO. This guide reveals cutting-edge workflows, troubleshooting insights, and practical translation of recent reference findings for reliable fibrin-based modeling.

• Tobramycin in Precision Microbiology: Assay Design and Data

  2026-06-16

  Explore how Tobramycin, a leading aminoglycoside antibiotic, empowers precision assay design and robust data integrity in microbiology research. This article uniquely bridges protocol optimization with advanced resistance analysis, offering practical and technical guidance beyond standard reviews.

• Ibotenic Acid in Circuit-Specific Pain Modeling: Precision T

  2026-06-16

  Explore how Ibotenic acid, a potent NMDA receptor agonist, enables circuit-targeted modeling of pain and neurodegeneration. This article uniquely dissects translational considerations for assay design and highlights advanced applications informed by recent neural circuitry breakthroughs.

• Strategic Use of Y-27632 in Translational Organoid Research

  2026-06-15

  This thought-leadership article explores the mechanistic underpinnings and translational strategies for leveraging the ROCK inhibitor Y-27632 in complex cell models, particularly patient-derived colorectal organoids. It blends cutting-edge mechanistic insights with actionable protocol guidance, situates APExBIO’s Y-27632 within the competitive landscape, and discusses the molecule’s growing role in translational and personalized medicine. Evidence from recent protocols and comparative studies is integrated to provide credible, workflow-driven recommendations for researchers.

• Strategic Advances in Membrane Protein Science with DDM

  2026-06-15

  This thought-leadership article empowers translational researchers to strategically harness n-Dodecyl-β-D-maltoside (DDM) for membrane protein studies. By integrating mechanistic insights, recent literature, and actionable workflow guidance, we illuminate the path from biochemical challenge to translational impact, using the case of Mycobacterium tuberculosis WecA as a touchstone for innovation. The discussion differentiates itself by bridging structural biology fundamentals with real-world protocol optimization and competitive landscape analysis, supporting informed decisions in drug discovery and precision medicine.

• Dynamic Binding Sites of GCGR for Small-Molecule Antagonists

  2026-06-14

  This study leverages both crystal structure and molecular dynamics simulations to systematically map the binding pockets of the human glucagon receptor (GCGR) for clinically relevant small-molecule antagonists. The work clarifies why MK 0893's binding mode is uniquely well-resolved, informs drug design for type 2 diabetes, and highlights the specificity and selectivity challenges inherent to GCGR-targeted therapies.

11838 records 1/790 page Next 12345 下5页 Last page